PFS
ALLO icon

Prospera Financial Services’s Allogene Therapeutics ALLO Stock Holding History

Prospera Financial Services’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-222
Closed -$3K – 856
2022
Q2 		$3K Hold
222
– – ﹤0.01% 1499
2022
Q1 		$2K Buy
+222
New +$2.31K ﹤0.01% 2448

Other funds holding ALLO

TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Prospera Financial Services's ALLO Position: Q3 2022 in Review

Prospera Financial Services sold out of Allogene Therapeutics (ALLO) in Q3 2022, closing a stake of 222 shares — an estimated $3K sold.

Prospera Financial Services first reported a position in ALLO in Q1 2022 and held it in 2 quarters. The position peaked at $3K in Q2 2022. 192 funds tracked by Wall St. Rank hold ALLO as of Q3 2022.

  • Prospera Financial Services reported no remaining Allogene Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Prospera Financial Services sold 222 Allogene Therapeutics shares in Q3 2022, an estimated $3K.
  • Prospera Financial Services first reported a position in Allogene Therapeutics in Q1 2022 and held it in 2 quarters.
  • Prospera Financial Services's Allogene Therapeutics position peaked at $3K in Q2 2022.
  • 192 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q3 2022.

Based on Prospera Financial Services's 13F filing for Q3 2022, filed 27 Oct 2022.